Safety Outcomes for JEMPERLI Monotherapy From the GARNET Trial

Safety profile established over more than 2 years1

Adverse reactions (≥10%) in patients with dMMR endometrial cancer who received JEMPERLI in GARNET

Adverse Reaction JEMPERLI (N=150)*
All Grades% Grade 3 or 4%
General and Administration Site
Fatigue 49 3.3
Pyrexia 13 0
Blood and Lymphatic System
Anemia 35 18
Nausea 32 0.7
Diarrhea 29 2.7
Constipation 23 0.7
Vomiting 23 0.7
Skin and Subcutaneous Tissue
Rash§ 21 0
Pruritus 19 1.3
Urinary tract infection 19 4
Metabolism and Nutrition
Decreased appetite 15 0
Respiratory, Thoracic, and Mediastinal
Cough 15 0
Musculoskeletal and Connective Tissue
Myalgia 10 0
Increased transaminases 13 4
Endocrine Disorders
Hypothyroidism 11 0

Toxicity was graded per National Cancer Institute Common Terminology Criteria for Adverse Events Version 4.03.

  • *Intent-to-treat population (N=150).
  • Includes fatigue and asthenia.
  • Includes anemia, decreased hemoglobin, iron deficiency, and iron deficiency anemia.
  • §Includes rash, rash maculo-papular, rash pruritic, erythema, and pemphigoid.
  • Includes increased alanine aminotransferase, increased aspartate aminotransferase, increased transaminases, and hypertransaminasemia.

dMMR=mismatch repair deficient.

Red light bulb icon

10% of patients permanently discontinued therapy due to adverse reactions1

  • Adverse reactions leading to discontinuation were increased transaminases, sepsis, bronchitis, pneumonitis, rash, pruritus, pancreatitis, encephalitis, and nephritis (15 patients total)1
  • The most common adverse reactions (≥20%) were fatigue/asthenia, anemia, nausea, diarrhea, constipation, vomiting, and rash1
  • Serious adverse reactions occurred in 38% of patients receiving JEMPERLI, including (>2% of patients) urinary tract infection (4%), sepsis (3.3%), acute kidney injury (2.7%), and abdominal pain (2.7%)1
  • A fatal adverse reaction occurred in one patient (0.7%) who received JEMPERLI, due to concurrent immune-mediated encephalitis and urinary tract infection1

Laboratory abnormalities from the GARNET trial1

Laboratory abnormalities that worsened from baseline to Grade 3 or 4 occurring in ≥1% of patients with dMMR endometrial cancer receiving JEMPERLI in GARNET

Laboratory Test JEMPERLI (N=150)
All Grades#% Grade 3 or 4#%
Decreased lymphocytes 46 15
Decreased leukocytes 21 2
Decreased neutrophils 17 2.7
Decreased albumin 36 2.7
Increased creatinine 33 3.4
Increased alkaline phosphatase 31 2.7
Increased aspartate aminotransferase 31 2
Increased alanine aminotransferase 25 4.7
Decreased sodium 29 5
Decreased magnesium 28 2
Decreased potassium 22 2
Increased calcium 8 2
  • Intention-to-treat population (N=150).
  • #Consists of new onset of laboratory abnormality or worsening of baseline laboratory abnormality.
Brochure icon

See downloadable resources and on-demand videos for JEMPERLI


Pie chart icon

See the GARNET trial results


Icon: JEMPERLI (dostarlimab-gxly) Dosing and Administration

Learn about JEMPERLI Dosing